Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in...

por Trarbach, T, Moehler, M, Heinemann, V, Köhne, C-H, Przyborek, M, Schulz, C, Sneller, V, Gallant, G, Kanzler, S
Publicado 2010

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).

por Warner, E., Goel, R., Chang, J., Chow, W., Verma, S., Dancey, J., Franssen, E., Dulude, H., Girouard, M., Correia, J., Gallant, G.
Publicado 1998